Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment

被引:126
|
作者
Palepu, A
Horton, NJ
Tibbetts, N
Meli, S
Samet, JH
机构
[1] Univ British Columbia, St Pauls Hosp, Dept Med, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V5Z 1M9, Canada
[2] DM STAT Inc, Medford, MA USA
[3] Boston Univ, Sch Med, Northampton, MA USA
[4] Boston Univ, Sch Publ Hlth, Northampton, MA USA
[5] Smith Coll, Dept Math, Northampton, MA 01063 USA
[6] Boston Univ, Dept Med, Gen Internal Med Sect, CARE Unit, Vancouver, WA USA
[7] Boston Univ, Dept Social & Behav Sci, Vancouver, WA USA
关键词
access; adherence; alcohol; antiretroviral therapy; HIV; substance abuse treatment; substance use;
D O I
10.1111/j.1360-0443.2003.00670.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aim We examined the association of substance abuse treatment with uptake, adherence and virological response to highly active antiretroviral therapy (HAART) among HIV-infected people with a history of alcohol problems. Design Prospective cohort study. Methods A standardized questionnaire was administered to 349 HIV-infected participants with a history of alcohol problems regarding demographics, substance use, use of substance abuse treatment and uptake of and adherence to HAART. These subjects were followed every 6 months for up to seven occasions. We defined substance abuse treatment services as any of the following in the past 6 months: 12 weeks in a half-way house or residential facility; 12 visits to a substance abuse counselor or mental health professional; or participation in any methadone maintenance program. Our outcome variables were uptake of antiretroviral therapy, 30-day self-reported adherence and HIV viral load suppression. Findings At baseline, 59% (205/349) of subjects were receiving HAART. Engagement in substance abuse treatment was independently associated with receiving antiretroviral therapy (adjusted OR; 95% CI: 1.70; 1.03-2.83). Substance abuse treatment was not associated with 30-day adherence or HIV viral load suppression. More depressive symptoms (0.48; 0.32-0.78) and use of drugs or alcohol in the previous 30 days (0.17; 0.11-0.28) were associated with worse 30-day adherence. HIV viral load suppression was positively associated with higher doses of antiretroviral medication (1.29; 1.15-1.45) and older age (1.04; 1.00-1.07) and negatively associated with use of drugs or alcohol in the previous 30 days (0.51; 0.33-0.78). Conclusion Substance abuse treatment was associated with receipt of HAART; however, it was not associated with adherence or HIV viral load suppression. Substance abuse treatment programs may provide an opportunity for HIV-infected people with alcohol or drug problems to openly address issues of HIV care including enhancing adherence to HAART.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [41] Effect of Anxiety Symptoms on Adherence to Highly Active Antiretroviral Therapy in HIV-Infected Women
    Roux, Perrine
    Carrieri, M. Patrizia
    Michel, Laurent
    Fugon, Lionel
    Marcellin, Fabienne
    Obadia, Yolande
    Spire, Bruno
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (09) : 1328 - 1329
  • [42] FOCUS ON THE LIVER: ALCOHOL USE, HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, AND LIVER DISEASE IN HIV-INFECTED PATIENTS
    Barve, Shirish
    Kapoor, Rama
    Moghe, Akshata
    Ramirez, Julio A.
    Eaton, John W.
    Gobejishvili, Leila
    Joshi-Barve, Swati
    McClain, Craig J.
    ALCOHOL RESEARCH & HEALTH, 2010, 33 (03) : 229 - 236
  • [43] Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users
    Arnsten, JH
    Demas, PA
    Grant, RW
    Gourevitch, MN
    Farzodegan, H
    Howard, AA
    Schoenboum, EE
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (05) : 377 - 381
  • [44] Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users
    Julia H. Arnsten
    Penelope A. Demas
    Richard W. Grant
    Marc N. Gourevitch
    Homayoon Farzadegan
    Andrea A. Howard
    Ellie E. Schoenbaum
    Journal of General Internal Medicine, 2002, 17 : 377 - 381
  • [45] Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy
    Henderson, M
    Safa, F
    Easterbrook, P
    Hotopf, M
    HIV MEDICINE, 2005, 6 (05) : 347 - 352
  • [46] Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
    Springer, Sandra Ann
    Chen, Shu
    Altice, Frederick L.
    JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2010, 87 (04): : 592 - 602
  • [47] Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
    Sandra Ann Springer
    Shu Chen
    Frederick L. Altice
    Journal of Urban Health, 2010, 87 : 592 - 602
  • [48] Antiretroviral therapy adherence among treatment-naive HIV-infected patients
    Chakraborty, Apurba
    Qato, Dima M.
    Awadalla, Saria S.
    Hershow, Ronald C.
    Dworkin, Mark S.
    AIDS, 2020, 34 (01) : 127 - 137
  • [49] Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy
    Risa, KJ
    Nepon, L
    Justis, JC
    Panwalker, A
    Berman, SM
    Cinti, S
    Wagener, MM
    Singh, N
    INTERNATIONAL JOURNAL OF STD & AIDS, 2002, 13 (10) : 706 - 713
  • [50] Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
    Dean, GL
    Edwards, SG
    Ives, NJ
    Matthews, G
    Fox, EF
    Navaratne, L
    Fisher, M
    Taylor, GP
    Miller, R
    Taylor, CB
    de Ruiter, A
    Pozniak, AL
    AIDS, 2002, 16 (01) : 75 - 83